<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098110</url>
  </required_header>
  <id_info>
    <org_study_id>P06124</org_study_id>
    <nct_id>NCT01098110</nct_id>
  </id_info>
  <brief_title>6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Fixed-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared With Placebo in Subjects With an Acute Exacerbation of Schizophrenia (Phase 3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, parallel-group, double-blind, fixed dose, 6-week trial of the
      efficacy and safety of asenapine compared with placebo in participants with an acute
      exacerbation of schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2010</start_date>
  <completion_date type="Actual">April 14, 2014</completion_date>
  <primary_completion_date type="Actual">April 14, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from baseline values that are negative represent an improvement in symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Positive Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Positive subscale measures symptoms of schizophrenia and consists of responses to 7 items (P1-P7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Positive subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Negative Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Negative subscale measures symptoms of schizophrenia and consists of responses to 7 items (N1-N7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Negative subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. . An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS General Psychopathology Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS General Psychopathology subscale measures symptoms of schizophrenia and consists of responses to 16 items (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS General Psychopathology subscale is the sum of the scores for all 16 items and ranges from 16 to 112, with a higher score indicating greater severity of symptoms.. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Factor Positive Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Marder Factor Positive symptom score measures symptoms of schizophrenia and consists of responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Positive symptom score is the sum of the scores for all 8 items and ranges from 8 to 56, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Factor Negative Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Marder Factor Negative symptom score measures symptoms of schizophrenia and consists of responses to 7 items (N1,N2,N3,N4,N6,G7,G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Negative symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Factor Disorganized Thought Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Marder Factor Disorganized Thought symptom score measures symptoms of schizophrenia and consists of responses to 7 items (P2,N5,G5,G10,G11,G13,G15). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Disorganized Thought symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Factor Hostility/Excitement Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Marder Factor Hostility/Excitement symptom score measures symptoms of schizophrenia and consists of responses to 4 items (P4,P7,G8,G14). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Hostility/Excitement symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Marder Factor Anxiety/Depression Symptom Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>PANSS Marder Factor Anxiety/Depression symptom score measures symptoms of schizophrenia and consists of responses to 4 items (G2,G3,G4,G6). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Anxiety/Depression symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were PANSS Responders.</measure>
    <time_frame>Day 42</time_frame>
    <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. The PANSS total score was determined at baseline and then at Day 42, and a participant with a 30% or greater reduction from baseline in PANSS total score at Day 42 was considered a PANSS responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impressions -Severity of Illness (CGI-S) Score.</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The CGI-S is a score that measures the severity of overall bipolar illness. The score ranges on a scale from 1 to 7, where 1 is normal, and 7 is very severely ill. Change from baseline values that are negative represent an improvement in symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Clinical Global Impressions - Improvement (CGI-I) Responders.</measure>
    <time_frame>Day 42</time_frame>
    <description>The CGI-I is a score on a 7-point scale for assessing the change from preceding phase of overall symptoms of bipolar disorder during the treatment of an acute episode or in longer term illness prophylaxis. Compared to the baseline, the CGI-I score ranges from 1 = very much improved since initiating treatment, to 7 = very much worse since initiating treatment. The CGI-I score was assessed at baseline and Day 42. Compared to the baseline measurement, a CGI-I responder had a score at Day 42 of 3 (minimally improved), 2 (much improved) or 1 (very much improved).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">532</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Asenapine 5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asenapine 10 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo BID for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 5 mg</intervention_name>
    <description>Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.</description>
    <arm_group_label>Asenapine 5 mg BID</arm_group_label>
    <arm_group_label>Asenapine 10 mg BID</arm_group_label>
    <other_name>SCH 900274</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asenapine 10 mg</intervention_name>
    <description>Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.</description>
    <arm_group_label>Asenapine 10 mg BID</arm_group_label>
    <other_name>SCH 900274</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A matching placebo of asenapine sublingual tablet not containing asenapine</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  current diagnosis of schizophrenia of paranoid, disorganized, catatonic, or
             undifferentiated (295.90) subtype

          -  minimum Positive and Negative Syndrome Scale (PANSS) total score of 60 at screening
             and Baseline.

          -  participant had a score of at least 4 in two or more of 5 items in the positive
             subscale of the PANSS at Screening and Baseline.

          -  participant confirmed by the investigator to be experiencing an acute exacerbation of
             schizophrenia as evidenced by ALL of the following:

               -  at the screening test, the duration of the current episode was no more than 2
                  months;

               -  current symptoms represented a dramatic and substantial change compared to the
                  participant's symptomatic state prior to the emergence of the current episode;

               -  participant was in need of changing medication or dosage to treat newly appeared
                  or worsened positive symptoms.

          -  participant had a Clinical Global Impressions-Severity (CGI-S) scale score of at least
             4 (moderately ill) at Baseline;

          -  responded positively to an antipsychotic medication in a prior episode.

          -  discontinued the use of all prohibited concomitant medications, with last dose taken
             no later than the evening prior to the baseline visit (For depot neuroleptic,
             discontinuation must have occurred more than 3 months prior to randomization).

          -  participants must agree to inpatient status for screening period and for up to 42 days
             of dosing and, for out-patient phase, had a caregiver or an identified responsible
             person (e.g., family member, social worker, case worker, or nurse) whom the
             investigator accepts and who has agreed to provide support to the participant to
             ensure compliance with study treatment, out-patient visits, and protocol procedures.

        Exclusion Criteria:

          -  not be treatment-refractory defined by the following criteria: (1) had been treated
             with at least two different atypical anti-psychotic agents at dosages equivalent to or
             greater than 600 mg/day of chlorpromazine (12 mg /day of haloperidol) for more than 4
             weeks, each without clinical response, or (2) has received clozapine for 12 weeks
             immediately preceding the screening.

          -  not have received treatment with 3 or more antipsychotic drugs, or dose-equivalents
             higher than 18 mg/day of haloperidol (equivalent 900 mg/day of chlorpromazine) within
             one month prior to randomization.

          -  not have a diagnosis of schizoaffective disorder; schizophrenia of residual subtype;
             schizophreniform disorder, or schizophrenia with course specifiers continuous, single
             episode in partial remission, or single episode in full remission

          -  not have a concurrent psychiatric disorder other than schizophrenia coded on Axis I;
             not have a primary diagnosis other than schizophrenia

          -  not have had a known diagnosis of borderline personality disorder, mental retardation
             or organic brain disorder.

          -  not have a 20% or greater decrease in PANSS total score from screening to baseline

          -  not have an imminent risk of self-harm or harm to others, in the investigator's
             opinion.

          -  not have a substance induced psychotic disorder or a behavioral disturbance thought to
             be due to substance abuse

          -  not be currently under involuntary in-patient confinement.

          -  not been previously treated with asenapine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>April 2, 2015</results_first_submitted>
  <results_first_submitted_qc>April 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2015</results_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asenapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=P06124&amp;kw=P06124&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Asenapine 5 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Asenapine 10 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID</title>
          <description>Participants received matching placebo BID for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176">Randomized participants</participants>
                <participants group_id="P2" count="182">Randomized participants</participants>
                <participants group_id="P3" count="174">Randomized participants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="175">Received at least one dose of trial medication</participants>
                <participants group_id="P2" count="181">Received at least one dose of trial medication</participants>
                <participants group_id="P3" count="174">Received at least one dose of trial medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Untreated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who received at least one dose of trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Asenapine 5 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Asenapine 10 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID</title>
          <description>Participants received matching placebo BID for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="181"/>
            <count group_id="B3" value="174"/>
            <count group_id="B4" value="530"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.41" spread="11.00"/>
                    <measurement group_id="B2" value="41.72" spread="11.10"/>
                    <measurement group_id="B3" value="41.11" spread="12.27"/>
                    <measurement group_id="B4" value="41.42" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="275"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.</title>
        <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from baseline values that are negative represent an improvement in symptoms.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.</title>
          <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. Change from baseline values that are negative represent an improvement in symptoms.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the last observation carried forward (LOCF) method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.24" lower_limit="-15.28" upper_limit="-9.20"/>
                    <measurement group_id="O2" value="-14.17" lower_limit="-17.12" upper_limit="-11.22"/>
                    <measurement group_id="O3" value="-0.95" lower_limit="-3.95" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant: p=&lt;0.05, two sided</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-11.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.42</ci_lower_limit>
            <ci_upper_limit>-7.16</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant: p=&lt;0.05, two sided</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-13.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.09</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.33</ci_lower_limit>
            <ci_upper_limit>-9.12</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Positive Symptom Score.</title>
        <description>PANSS Positive subscale measures symptoms of schizophrenia and consists of responses to 7 items (P1-P7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Positive subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Positive Symptom Score.</title>
          <description>PANSS Positive subscale measures symptoms of schizophrenia and consists of responses to 7 items (P1-P7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Positive subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.31" lower_limit="-5.29" upper_limit="-3.33"/>
                    <measurement group_id="O2" value="-4.63" lower_limit="-5.59" upper_limit="-3.68"/>
                    <measurement group_id="O3" value="-0.85" lower_limit="-1.82" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-3.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.80</ci_lower_limit>
            <ci_upper_limit>-2.13</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-3.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.11</ci_lower_limit>
            <ci_upper_limit>-2.46</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Negative Symptom Score.</title>
        <description>PANSS Negative subscale measures symptoms of schizophrenia and consists of responses to 7 items (N1-N7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Negative subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. . An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. One participant from the 5 mg BID arm was missing a post-baseline measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Negative Symptom Score.</title>
          <description>PANSS Negative subscale measures symptoms of schizophrenia and consists of responses to 7 items (N1-N7). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Negative subscale sums all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. . An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. One participant from the 5 mg BID arm was missing a post-baseline measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" lower_limit="-3.50" upper_limit="-1.93"/>
                    <measurement group_id="O2" value="-3.27" lower_limit="-4.03" upper_limit="-2.51"/>
                    <measurement group_id="O3" value="-0.24" lower_limit="-1.02" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-2.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>-1.41</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-3.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.08</ci_lower_limit>
            <ci_upper_limit>-1.97</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS General Psychopathology Score.</title>
        <description>PANSS General Psychopathology subscale measures symptoms of schizophrenia and consists of responses to 16 items (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS General Psychopathology subscale is the sum of the scores for all 16 items and ranges from 16 to 112, with a higher score indicating greater severity of symptoms.. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS General Psychopathology Score.</title>
          <description>PANSS General Psychopathology subscale measures symptoms of schizophrenia and consists of responses to 16 items (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS General Psychopathology subscale is the sum of the scores for all 16 items and ranges from 16 to 112, with a higher score indicating greater severity of symptoms.. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.26" lower_limit="-6.81" upper_limit="-3.72"/>
                    <measurement group_id="O2" value="-6.34" lower_limit="-7.84" upper_limit="-4.83"/>
                    <measurement group_id="O3" value="0.19" lower_limit="-1.34" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-5.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.56</ci_lower_limit>
            <ci_upper_limit>-3.35</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Statistical significant: p=&lt;0.05, two sided</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-6.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.62</ci_lower_limit>
            <ci_upper_limit>-4.44</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Factor Positive Symptom Score.</title>
        <description>PANSS Marder Factor Positive symptom score measures symptoms of schizophrenia and consists of responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Positive symptom score is the sum of the scores for all 8 items and ranges from 8 to 56, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Factor Positive Symptom Score.</title>
          <description>PANSS Marder Factor Positive symptom score measures symptoms of schizophrenia and consists of responses to 8 items (P1,P3,P5,P6,N7,G1,G9,G12). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Positive symptom score is the sum of the scores for all 8 items and ranges from 8 to 56, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.78" lower_limit="-5.75" upper_limit="-3.81"/>
                    <measurement group_id="O2" value="-5.03" lower_limit="-5.98" upper_limit="-4.09"/>
                    <measurement group_id="O3" value="-1.37" lower_limit="-2.33" upper_limit="-0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-3.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.72</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-3.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.67</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.97</ci_lower_limit>
            <ci_upper_limit>-2.35</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Factor Negative Symptom Score.</title>
        <description>PANSS Marder Factor Negative symptom score measures symptoms of schizophrenia and consists of responses to 7 items (N1,N2,N3,N4,N6,G7,G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Negative symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Factor Negative Symptom Score.</title>
          <description>PANSS Marder Factor Negative symptom score measures symptoms of schizophrenia and consists of responses to 7 items (N1,N2,N3,N4,N6,G7,G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Negative symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" lower_limit="-3.58" upper_limit="-1.96"/>
                    <measurement group_id="O2" value="-3.35" lower_limit="-4.14" upper_limit="-2.55"/>
                    <measurement group_id="O3" value="-0.41" lower_limit="-1.21" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-2.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.47</ci_lower_limit>
            <ci_upper_limit>-1.26</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-2.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.03</ci_lower_limit>
            <ci_upper_limit>-1.84</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Factor Disorganized Thought Symptom Score.</title>
        <description>PANSS Marder Factor Disorganized Thought symptom score measures symptoms of schizophrenia and consists of responses to 7 items (P2,N5,G5,G10,G11,G13,G15). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Disorganized Thought symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. One participant from the 5 mg BID arm was missing a post-baseline measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Factor Disorganized Thought Symptom Score.</title>
          <description>PANSS Marder Factor Disorganized Thought symptom score measures symptoms of schizophrenia and consists of responses to 7 items (P2,N5,G5,G10,G11,G13,G15). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Disorganized Thought symptom score is the sum of the scores for all 7 items and ranges from 7 to 49, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. One participant from the 5 mg BID arm was missing a post-baseline measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.48" lower_limit="-3.23" upper_limit="-1.73"/>
                    <measurement group_id="O2" value="-2.85" lower_limit="-3.57" upper_limit="-2.12"/>
                    <measurement group_id="O3" value="0.24" lower_limit="-0.50" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-2.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.73</ci_lower_limit>
            <ci_upper_limit>-1.70</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-3.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.51</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>-2.08</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Factor Hostility/Excitement Symptom Score.</title>
        <description>PANSS Marder Factor Hostility/Excitement symptom score measures symptoms of schizophrenia and consists of responses to 4 items (P4,P7,G8,G14). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Hostility/Excitement symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Factor Hostility/Excitement Symptom Score.</title>
          <description>PANSS Marder Factor Hostility/Excitement symptom score measures symptoms of schizophrenia and consists of responses to 4 items (P4,P7,G8,G14). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Hostility/Excitement symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" lower_limit="-1.35" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-1.40" lower_limit="-1.97" upper_limit="-0.84"/>
                    <measurement group_id="O3" value="0.86" lower_limit="0.28" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-1.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.41</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-2.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.04</ci_lower_limit>
            <ci_upper_limit>-1.47</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Marder Factor Anxiety/Depression Symptom Score.</title>
        <description>PANSS Marder Factor Anxiety/Depression symptom score measures symptoms of schizophrenia and consists of responses to 4 items (G2,G3,G4,G6). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Anxiety/Depression symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Marder Factor Anxiety/Depression Symptom Score.</title>
          <description>PANSS Marder Factor Anxiety/Depression symptom score measures symptoms of schizophrenia and consists of responses to 4 items (G2,G3,G4,G6). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS Marder Factor Anxiety/Depression symptom score is the sum of the scores for all 4 items and ranges from 4 to 28, with a higher score indicating greater severity of symptoms. An improvement in symptoms is represented by change from baseline values that are negative.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" lower_limit="-2.01" upper_limit="-1.08"/>
                    <measurement group_id="O2" value="-1.67" lower_limit="-2.12" upper_limit="-1.22"/>
                    <measurement group_id="O3" value="-0.13" lower_limit="-0.59" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-1.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>-0.78</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-1.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were PANSS Responders.</title>
        <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. The PANSS total score was determined at baseline and then at Day 42, and a participant with a 30% or greater reduction from baseline in PANSS total score at Day 42 was considered a PANSS responder.</description>
        <time_frame>Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were PANSS Responders.</title>
          <description>PANSS total score measures symptoms of schizophrenia and consists of responses to 30 items: 7 items from the positive subscale (P1-P7), 7 items from the negative subscale (N1-N7) and 16 items from the general psychopathology subscale (G1-G16). Responses to each item range from 1 = absence of symptom, to 7 = most extreme symptoms. The PANSS total score is the sum of the scores for all 30 items, and ranges from 30 to 210, with a higher score indicating greater severity of symptoms. The PANSS total score was determined at baseline and then at Day 42, and a participant with a 30% or greater reduction from baseline in PANSS total score at Day 42 was considered a PANSS responder.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="32.0" upper_limit="47.0"/>
                    <measurement group_id="O2" value="43.8" lower_limit="36.4" upper_limit="51.4"/>
                    <measurement group_id="O3" value="20.7" lower_limit="14.9" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Adjusted for region.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>28.1</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for region.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impressions -Severity of Illness (CGI-S) Score.</title>
        <description>The CGI-S is a score that measures the severity of overall bipolar illness. The score ranges on a scale from 1 to 7, where 1 is normal, and 7 is very severely ill. Change from baseline values that are negative represent an improvement in symptoms.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impressions -Severity of Illness (CGI-S) Score.</title>
          <description>The CGI-S is a score that measures the severity of overall bipolar illness. The score ranges on a scale from 1 to 7, where 1 is normal, and 7 is very severely ill. Change from baseline values that are negative represent an improvement in symptoms.</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-0.86" upper_limit="-0.52"/>
                    <measurement group_id="O2" value="-0.77" lower_limit="-0.94" upper_limit="-0.61"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-0.35" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>Least square (LS) means difference</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Change from baseline a response variable, baseline score a covariate, treatment groups and regions as explanatory variables.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-0.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Clinical Global Impressions - Improvement (CGI-I) Responders.</title>
        <description>The CGI-I is a score on a 7-point scale for assessing the change from preceding phase of overall symptoms of bipolar disorder during the treatment of an acute episode or in longer term illness prophylaxis. Compared to the baseline, the CGI-I score ranges from 1 = very much improved since initiating treatment, to 7 = very much worse since initiating treatment. The CGI-I score was assessed at baseline and Day 42. Compared to the baseline measurement, a CGI-I responder had a score at Day 42 of 3 (minimally improved), 2 (much improved) or 1 (very much improved).</description>
        <time_frame>Day 42</time_frame>
        <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
        <group_list>
          <group group_id="O1">
            <title>Asenapine 5 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Asenapine 10 mg BID</title>
            <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID</title>
            <description>Participants received matching placebo BID for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Clinical Global Impressions - Improvement (CGI-I) Responders.</title>
          <description>The CGI-I is a score on a 7-point scale for assessing the change from preceding phase of overall symptoms of bipolar disorder during the treatment of an acute episode or in longer term illness prophylaxis. Compared to the baseline, the CGI-I score ranges from 1 = very much improved since initiating treatment, to 7 = very much worse since initiating treatment. The CGI-I score was assessed at baseline and Day 42. Compared to the baseline measurement, a CGI-I responder had a score at Day 42 of 3 (minimally improved), 2 (much improved) or 1 (very much improved).</description>
          <population>All randomized participants who received at least one dose of trial medication, and had baseline and at least one post-baseline PANSS measurement. Dropout or missing data are imputed by the LOCF method.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="55.9" upper_limit="70.8"/>
                    <measurement group_id="O2" value="70.2" lower_limit="62.9" upper_limit="76.8"/>
                    <measurement group_id="O3" value="41.4" lower_limit="34.0" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for region.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.0</ci_lower_limit>
            <ci_upper_limit>32.4</ci_upper_limit>
            <estimate_desc>Asenapine 5 mg BID minus Placebo BID</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted for region.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.9</ci_lower_limit>
            <ci_upper_limit>38.8</ci_upper_limit>
            <estimate_desc>Asenapine 10 mg BID minus Placebo BID</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 49 days for non-serious adverse events (AEs), and up to 79 days for serious AEs</time_frame>
      <desc>Participants who received at least one dose of trial medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Asenapine 5 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet BID for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Asenapine 10 mg BID</title>
          <description>Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID</title>
          <description>Participants received matching placebo BID for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="175"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Schizophrenia, paranoid type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="181"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="175"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="175"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="175"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="181"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="181"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="175"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="175"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="181"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="175"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="174"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="175"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="181"/>
                <counts group_id="E3" events="44" subjects_affected="42" subjects_at_risk="174"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts, and to review and comment on the data analysis and presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

